Ozeki T, et al. - In this prospective observational study, researchers assessed the effectiveness of a 2-month, short-term steroid regimen in the treatment of adult patients with steroid-sensitive minimal change disease (MCD) (n = 35). These subjects were initiated on a short-term steroid regimen between January 2015 and June 2016, and had biopsy-proven MCD, age ≥20 years, first episode of nephrotic syndrome, and had attained complete remission within 4 weeks. These were given prednisolone at an initial dose of 0.8–1.0 mg/kg/day and continued for 4–6 weeks and dosage was reduced to 0.5–0.6 mg/kg/alternate day and continued for 4 weeks. Controls were selected from previous adult MCD cohort and were given conventional steroid treatment. During the observational period (median: 17.3 months), significantly lower cumulative steroid dose was reported in the short-term group vs in the conventional group. Overall, the short-term steroid regimen may effectively treat this patient population.